The 15 most recent market catalysts affecting $OTLK, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 27, 2026
Corporate Catalyst
Neutral
Impact 55
Outlook Therapeutics Announces Appointment Of Kevin Lundquist As CFO Effective September 1
The appointment of a new CFO, Kevin Lundquist, for Outlook Therapeutics is a corporate governance event. While not immediately market-moving in terms of product development or fina…
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target
This 8-K filing discloses that BTIG analyst Julian Harrison has reiterated a 'Buy' rating for Outlook Therapeutics (OTLK) and maintained a $4 price target. This action signals cont…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 85
Outlook Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results.
The headline indicates a direct negative corporate catalyst for Outlook Therapeutics (OTLK). Worse-than-expected sales results directly impact a company's financial health and futu…
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 95
Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call
Outlook Therapeutics has achieved a major milestone with the FDA approval of Lytenava, the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD. This approval signi…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 95
Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M Estimate
Outlook Therapeutics announced its Q3 earnings, reporting adjusted EPS that met analyst expectations. However, the company's sales of $9,000 were a catastrophic miss, falling short…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 65
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Outlook Therapeutics is set to release its Q3 earnings, with analysts forecasting a significant reduction in loss per share but a decline in revenue. This information is crucial fo…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 85
Outlook Therapeutics shares are trading lower after the company announced the pricing of its $55 million offering of 55,555,556 shares and warrants at $0.99 combined price per share.
This headline represents a significant corporate catalyst for Outlook Therapeutics. The pricing of a $55 million offering at a combined price of $0.99 per share and warrant indicat…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 75
Reported Earlier, Outlook Therapeutics Prices $55.0M Offering Of 55,555,556 Shares And Warrants At $0.99 Combined Price Per Share
This headline indicates a significant capital raise for Outlook Therapeutics through a combined offering of shares and warrants. While the $55.0 million infusion provides crucial f…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 85
Outlook Therapeutics shares are trading lower after the company announced a proposed public offering.
The announcement of a proposed public offering by Outlook Therapeutics is a significant corporate catalyst. Public offerings, especially when not accompanied by strong positive new…
Aug 12, 2026
Corporate Catalyst
Neutral
Impact 75
Outlook Therapeutics Launches Underwritten Public Offering Of Common Stock And Warrants To Fund LYTENAVA Launch; No Financial Terms Disclosed
Outlook Therapeutics announced an underwritten public offering of common stock and warrants. This move is crucial for the company as it seeks to raise capital to support the commer…
Aug 12, 2026
Corporate Catalyst
Neutral
Impact 75
Outlook Therapeutics Terminated May 13, 2026 Prospectus Supplement For ATM Offering Agreement With H.C. Wainwright
The termination of an At-The-Market (ATM) offering agreement typically signals that a company no longer needs to raise capital through that specific mechanism, or has found a more …
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 95
Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection
Outlook Therapeutics (OTLK) has secured FDA approval for ONS-5010/LYTENAVA, a significant milestone after multiple prior rejections. This approval is a major positive catalyst for …
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Upgrades Outlook Therapeutics to Buy, Announces $4 Price Target
This 8-K filing discloses that BTIG analyst Julian Harrison has upgraded Outlook Therapeutics (OTLK) from a 'Neutral' to a 'Buy' rating and established a $4 price target. This is a…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 95
Outlook Therapeutics Says FDA Approves LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration, Commonly Known As Wet AMD
Outlook Therapeutics has received FDA approval for LYTENAVA (bevacizumab-vikg) for the treatment of wet AMD. This is a significant event as it establishes LYTENAVA as the first and…
Jul 17, 2026
Corporate Catalyst
Neutral
Impact 55
Outlook Therapeutics Files Prospectus For Offering 17.258M Common Shares On Behalf Of Selling Stockholders
Outlook Therapeutics has filed a prospectus to register the resale of 17.258 million common shares by existing selling stockholders. This is a secondary offering, meaning the compa…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.